Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks
A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identif...
Author: cancergrace
Added: 07/06/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts